Redwire Partners with Eli Lilly and Company on Second Spaceflight Mission to Conduct Additional Research on Chronic Diseases Following Successful Results
12 März 2024 - 12:30PM
Business Wire
This Marks Lilly’s Second Spaceflight to Use the Pharmaceutical
In-Space Laboratory in Four Months
Redwire Corporation (NYSE: RDW), a leader in space
infrastructure for the next generation space economy, announced
today that it is partnering with Eli Lilly and Company (Lilly) on a
second spaceflight mission using its in-space pharmaceutical
manufacturing platform, PIL-BOX. On this second mission
(PIL-02)Lilly researchers will be conducting an experiment aimed at
accelerating the discovery of novel medicines against chronic
diseases. Following the successful results of the PIL-01
experiment, which demonstrated that microgravity benefited insulin
crystal growth, Lilly researchers will use the PIL-02 mission to
expand their understanding of crystal formulations and how they
impact overall drug discovery and development.
“We are excited to partner with Lilly again for a second
spaceflight mission to discover a new way to advance protein
crystallization, which may provide helpful information to help
accelerate drug discovery,” said Redwire In-Space Industries
President John Vellinger. “Building off our successful first
mission, the Redwire PIL-BOX platform presents pharmaceutical
researchers with a new way to analyze crystal growth and
potentially accelerate drug discovery and development
timelines.”
Redwire’s PIL-BOX platform offers pharmaceutical companies and
biomedical researchers novel and flexible services to grow
small-batch crystals of protein-based pharmaceuticals along with
other key pharmaceutically relevant large and small molecules for
research. Understanding crystal growth can inform the entire drug
discovery and development process for small and large molecule
pharmaceuticals as companies look to deliver new, optimized
treatments to help patients.
Relatedly, through a separate investigation, Redwire will also
be launching a modified version of the PIL-BOX platform, called
PIL-BOX Dynamic Microscopy Cassette, which will enable researchers
to observe the crystal growth process as it happens in space.
PIL-BOX is part of Redwire’s broad portfolio of space biotech and
microgravity development capabilities targeting the use of the
unique environment in space to enhance life on Earth. The PIL-02
experiment will launch onboard SpaceX’s 30th cargo resupply
services mission (SpX-30) for NASA to the International Space
Station.
About Redwire Redwire Corporation (NYSE:RDW) is a global
space infrastructure and innovation company enabling civil,
commercial, and national security programs. Redwire’s proven and
reliable capabilities include avionics, sensors, power solutions,
critical structures, mechanisms, radio frequency systems,
platforms, missions, and microgravity payloads. Redwire combines
decades of flight heritage and proven experience with an agile and
innovative culture. Redwire’s approximately 700 employees working
from 14 facilities located throughout the United States and Europe
are committed to building a bold future in space for humanity,
pushing the envelope of discovery and science while creating a
better world on Earth. For more information, please visit
redwirespace.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240312868280/en/
Media Contact: Emily Devine Emily.Devine@redwirespace.com
305-632-9137
OR
Investors: investorrelations@redwirespace.com
904-425-1431
Redwire (NYSE:RDW)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Redwire (NYSE:RDW)
Historical Stock Chart
Von Mai 2023 bis Mai 2024